154 related articles for article (PubMed ID: 26252311)
1. A Clinical Trial of Optimal Time Interval Between Ablation and Diagnostic Activity When a Pretherapy RAI Scanning Is Performed on Patients With Differentiated Thyroid Carcinoma.
Yin Y; Mao Q; Chen S; Li N; Li X; Li Y
Medicine (Baltimore); 2015 Aug; 94(31):e1308. PubMed ID: 26252311
[TBL] [Abstract][Full Text] [Related]
2. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
3. The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer.
Chen MK; Yasrebi M; Samii J; Staib LH; Doddamane I; Cheng DW
Thyroid; 2012 Mar; 22(3):304-9. PubMed ID: 22300251
[TBL] [Abstract][Full Text] [Related]
4. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
5. A quantitative study about thyroid stunning after diagnostic whole-body scanning with 74 MBq 131I in patients with differentiated thyroid carcinoma.
Yin Y; Mao Q; Chen S; Li N; Li X; Li Y
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):455-61. PubMed ID: 26416037
[TBL] [Abstract][Full Text] [Related]
6. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
Silberstein EB
J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
[TBL] [Abstract][Full Text] [Related]
8. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer.
Van Nostrand D; Aiken M; Atkins F; Moreau S; Garcia C; Acio E; Burman K; Wartofsky L
Thyroid; 2009 Aug; 19(8):849-55. PubMed ID: 19281428
[TBL] [Abstract][Full Text] [Related]
9. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
Rubello D; Mazzarotto R; Casara D
Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
[TBL] [Abstract][Full Text] [Related]
10. Stunning phenomenon after a radioactive iodine- ¹³¹I diagnostic whole-body scan: Is it really a point of clinical consideration?
Amin A; Amin M; Badwey A
Nucl Med Commun; 2013 Aug; 34(8):771-6. PubMed ID: 23708870
[TBL] [Abstract][Full Text] [Related]
11. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation.
Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH
Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake.
Rosário PW; Reis JS; Barroso AL; Rezende LL; Padrão EL; Fagundes TA
Nucl Med Commun; 2004 Nov; 25(11):1077-81. PubMed ID: 15577584
[TBL] [Abstract][Full Text] [Related]
13. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
14. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.
Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H
Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773
[TBL] [Abstract][Full Text] [Related]
15. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
Yap BK; Murby B
J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
[TBL] [Abstract][Full Text] [Related]
16. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
Muratet JP; Daver A; Minier JF; Larra F
J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
[TBL] [Abstract][Full Text] [Related]
17. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution?
Souza Rosário PW; Barroso AL; Rezende LL; Padrão EL; Fagundes TA; Penna GC; Purisch S
Clin Nucl Med; 2004 Dec; 29(12):795-8. PubMed ID: 15545881
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
19. The so-called stunning of thyroid tissue.
Sisson JC; Avram AM; Lawson SA; Gauger PG; Doherty GM
J Nucl Med; 2006 Sep; 47(9):1406-12. PubMed ID: 16954546
[TBL] [Abstract][Full Text] [Related]
20. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
